'Sun Pharma eyes deals to push specialty play, EM business'

Sun Pharma, India's largest drugmaker, is looking at acquisitions to boost its specialty pipeline and strengthen emerging markets business. "Our focus on M&A will be on augmenting the pipeline for specialty and further strengthening our footprint in emerging markets," said CS Muralidharan, chief financial officer of Sun Pharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9pxieud
via IFTTT